secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001193125-26-188935
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin Q1 total revenue up 7% to $45.1M; operating loss narrows 32%; cash flow positive
--------------------------------------------------------------------------------

- Total net revenue $45.1M (+7% YoY); U.S. product revenue $35.6M flat; European revenue $4.9M (-9%); ROW $2.8M.
- Operating loss narrowed to $11.3M from $16.8M; net loss $10.5M ($0.03 EPS) vs $15.7M ($0.04 EPS).
- Cash and investments $307.8M; debt-free; second consecutive quarter of positive cash flow.
- Reaffirms full-year 2026 positive cash flow; targeting ~$70M cost savings; restructuring charges $39.6M cumulative.
- Recordati launched VAZKEPA in 10 European countries; U.S. VAZCEPA branded Rx up 17% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000119312526188935/0001193125-26-188935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000119312526188935/amrn-20260429.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-188935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer